Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: A systematic review

Neuroepidemiology

Volumn 23, Issue 4, 2004, Pages 159-169

  Szekely, Christine A ^a   Thorne, Jennifer E ^a,b   Zandi, Peter P ^a   Ek, Mats ^a   Messias, Erick ^a   Breitner, John C S ^c   Goodman, Steven N ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Meta analysis; Nonsteroidal anti inflammatory agents; Observational studies; Prevention; Systematic review

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; CLINICAL TRIAL; DATA ANALYSIS; DRUG EXPOSURE; HUMAN; MEDLINE; META ANALYSIS; QUALITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EVIDENCE-BASED MEDICINE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 3242803587     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078501     Document Type: Review

References (70)

1. Selkoe DJ: Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 2000;924:17-25.
2. Brookmeyer R, Gray S: Methods for projecting the incidence and prevalence of chronic diseases in aging populations: application to Alzheimer's disease. Stat Med 2000;19:1481-1493.
3. Breitner JC, Zandi PP: Do nonsteroidal antiin-flammatory drugs reduce the risk of Alzheimer's disease? N Engl J Med 2001;345:1567-1568.
4. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-432.
5. Henderson VW: The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 1997;48(5 suppl 7):S27-S35.
6. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD, Metter E: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517-1521.
7. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC: Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA 2002;288:2123-2129.
8. Commenges D, Scotet V, Renaud S, Jacqmin-Gadda H, Barberger-Gateau P, Dartigues JF: Intake of flavonoids and risk of dementia. Eur J Epidemiol 2000;16:357-363.
9. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S, Breteler MB: Wine consumption and dementia in the elderly: A prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997;153:185-192.
10. 2 receptor antagonists: The Cache County study. Neurology 2000;54:2066-2071.
11. 2 blocking drugs. Neurobiol Aging 1995;16:523-530.
12. McGeer PL, Schulzer M, McGeer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996;47:425-432.
13. McGeer PL, McGeer E, Rogers J, Sibley J: Anti-inflammatory drugs and Alzheimer disease. Lancet 1990;335:1037.
14. Myllykangas-Luosujarvi R, Isomaki H: Alzheimer's disease and rheumatoid arthritis. Br J Rheumatol 1994;33:501-502.
15. Jenkinson ML, Bliss MR, Brain AT, Scott DL: Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 1989;28:86-88.
16. Broe GA, Henderson AS, Creasey H, McCusker E, Korten AE, Jorm AF, Longley W, Anthony JC: A case-control study of Alzheimer's disease in Australia. Neurology 1990;40:1698-1707.
17. McGeer PL, Harada N, Kimura H, McGeer EG: Prevalence of dementia amongst elderly Japanese with leprosy: Apparent effect of chronic drug therapy. Dementia 1992;3:146-149.
18. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N: A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201.
19. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ: Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003;289:2819-2826.
20. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P: Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.
21. Zandi PP, Breitner JC: Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 2001;22:811-817.
22. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T: Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
23. Giulian D: Microglia and the immune pathology of Alzheimer disease. Am J Hum Genet 1999;65:13-18.
24. Casper D, Yaparpalvi U, Rempel N, Werner P: Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 2000;289:201-204.
25. Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, Currie J, Ames D, Weidemann A, Fischer P: The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem 1990;265:15977-15983.
26. Etminan M, Gill S, Samii A: Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. BMJ 2003;327:128-132.
27. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, DSM-III-R, ed 3, revised. Washington, American Psychiatric Association, 1987.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
29. Stata Statistical Software: Release 7.0. College Station. Texas, Stata Corporation, 2000.
30. Paganini-Hill A, Clark LJ, Henderson VW, Birge SJ: Clock drawing: Analysis in a retirement community. J Am Geriatr Soc 2001;49:941-947.
31. Beard CM, Kokman E, Kurland LT: Rheumatoid arthritis and susceptibility to Alzheimer's disease. Lancet 1991;337:1426.
32. Breteler MM, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, et al: Medical history and the risk of Alzheimer's disease: A collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991;20(suppl 2):36-42.
33. Li G, Shen YC, Li YT, Chen CH, Zhau YW, Silverman JM: A case-control study of Alzheimer's disease in China. Neurology 1992;42:1481-1488.
34. Graves AB, White E, Koepsell TD, Reifl er BV, van Belle G, Larson EB, Raskind M: A case-control study of Alzheimer's disease. Ann Neurol 1990;28:766-774.
35. French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B: A case-control study of dementia of the Alzheimer type. Am J Epidemiol 1985;121:414-421.
36. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T: Alzheimer's disease: A study of epidemiological aspects. Ann Neurol 1984;15:335-341.
37. Jones RW: Inflammation and Alzheimer's disease. Lancet 2001;358:436-437.
38. Delanty N, Vaughan C: Risk of Alzheimer's disease and duration of NSAID use. Neurology 1998;51:652.
39. Halliday GM, Shepherd CE, McCann H, Reid WG, Grayson DA, Broe GA, Kril JJ: Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol 2000;57:831-836.
40. Haruda FD: Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:2116.
41. Mortimer JA: New findings consistent with Alzheimer's-NSAIDs link. Neurobiol Aging 1998;19:615-616.
42. Van Muiswinkel FL, Eikelenboom P: Do nonsteroidal anti-inflammatory drugs have a protective effect against dementia? Drugs Aging 1996;9:1-7.
43. Kokmen E, Beard CM, O'Brien PC, Kurland LT: Epidemiology of dementia in Rochester, Minnesota. Mayo Clin Proc 1996;71:275-282.
44. in 't Veld BA, Launer LJ, Hoes AW, Ott A, Hofman A, Breteler MM, Stricker BH: NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 1998;19:607-611.
45. in 't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521.
46. Wolfson C, Perrault A, Moride Y, Esdaile JM, Abenhaim L, Momoli F: A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: Are they protective? Neuroepidemiology 2002;21:81-86.
47. The Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-2080.
48. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J: Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-55.
49. Henderson AS, Jorm AF, Christensen H, Jacomb PA, Korten AE: Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiatry 1997;12:926-930.
50. Mackenzie IR, Munoz DG: Nonsteroidal antiinflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998;50:986-990.
51. Mackenzie IR, Munoz DG: Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol 2001;58:517-519.
52. Harris Y, Gorelick PB, Freels S, Billingsley M, Brown N, Robinson D: Neuroepidemiology of vascular and Alzheimer's dementia among African-American women. J Natl Med Assoc 1995;87:741-745.
53. Lucca U, Tettamanti M, Forloni G, Spagnoli A: Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994;36: 854-856.
54. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A: Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995;45:1441-1445.
55. Broe GA, Grayson DA, Creasey HM, Waite LM, Casey BJ, Bennett HP, Brooks WS, Halliday GM: Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000;57:1586-1591.
56. Stewart WF, Kawas C, Corrada M, Metter EJ: Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-632.
57. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC: Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 1994;44:227-232.
58. Beard CM, Waring SC, O'Brien PC, Kurland LT, Kokmen E: Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: A case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 1998;73:951-955.
59. 2 receptor antagonists: The Cache County Study. Neurology 2002;59:880-886.
60. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I: Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156:445-453.
61. Landi F, Cesari M, Onder G, Russo A, Torre S, Bernabei R: Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am J Geriatr Psychiatry 2003;11:179-185.
62. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, ed 4, revised. Washington, American Psychiatric Association, 1994.
63. Breitner JC: Exposure classifi cation: the bugbear of dementia epidemiology. Neurobiol Aging 1998;19:613-614.
64. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO: Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989;262:2551-2556.
65. Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, D'Agostino RB, White LR: Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992;42:115-119.
66. Henderson AS, Easteal S, Jorm AF, Mackinnon AJ, Korten AE, Christensen H, Croft L, Jacomb PA: Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 1995;346:1387-1390.
67. Fourrier A, Letenneur L, Begaud B, Dartigues JF: Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: Inconclusive results from a population-based cohort study. J Clin Epidemiol 1996;49:1201.
68. Ioannidis JP: Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998;279:281-286.
69. Breitner JC: New epidemiologic strategies in Alzheimer's disease may provide clues to prevention and cause. Neurobiol Aging. 1994;15(suppl 2):S175-S177.
70. Martin BK, Meinert CL, Breitner JC: Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials 2002;23:93-99.